Levilactobacillus Brevis Oral Health

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 30, 2022

Primary Completion Date

May 30, 2023

Study Completion Date

November 30, 2023

Conditions
Oral HealthOral Disease
Interventions
DIETARY_SUPPLEMENT

Levilactobacillus brevis CNCM I-5566

Participants will take four Mucomixx tablets (containing Levilactobacillus brevis CNCM I-5566) daily for 28 days. The tablets should be taken after each of the following meals: breakfast, lunch, afternoon break, and dinner.

DIETARY_SUPPLEMENT

Placebo

Participants will take four placebo tablets daily for 28 days. The tablets should be taken after each of the following meals: breakfast, lunch, afternoon break, and dinner.

Trial Locations (1)

67100

University of L'Aquila, L’Aquila

All Listed Sponsors
lead

University of L'Aquila

OTHER